MEETING PREVIEW: Companies and trends to watch at JP Morgan conference
This article was originally published in Scrip
Since both seasoned life science investors and relative newcomers to the sector will have time over the holidays to rest prior to the annual JP Morgan Healthcare conference in San Francisco, Big Pharma executives and small biotech CEOs alike may want to spend their time out of the office in late December and early January perfecting answers to investor questions about research, acquisition, product launch and reimbursement strategies for 2013.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.